Featured Publications

Featured publications

WID epigenetic tests for women’s cancers

Barrett, Herzog et al. Nature Communications, 2022.
Barrett, Sundström, Jones et al. Genome Medicine, 2022.
Barrett, Jones, Evans, Herzog et al. International Journal of Cancer, 2023.

Herzog et al. npj Precision Oncology. 2023.

We assessed the potential of epigenetic footprints in cervical screening samples to detect and risk predict breast, ovarian, womb and cervical cancers. Our research has the potential to change the future of personalised preventive medicine.

Featured Publications

qPCR test for womb cancer detection

Evans, Reisel, Jones, Bajrami et al, Lancet Oncology, 2023
Illah, Scott, Redl et al, International Journal of Cancer, 2024

Herzog, Marin et al. Journal of Clinical Oncology, 2022
Schreiberhuber et al, International Journal of Cancer, 2022

The WID™-qEC test detects endometrial cancer using qPCR with high accuracy in a cervical smear or vagina swab. The test has been validated in women with abnormal vaginal bleeding.

Featured publication

WID-qCIN test for cervical cancer detection

Schrieberhuber, Barrett, Wang et al, Nature Medicine

Validation of WID-qCIN test performance in HPV positive samples from a cohort of >28,000 women attending cervical screening.

Featured Publication

WID epigenetic clocks

Barrett et al., 2022, Genome Biology

We describe a new epigenetic clock that highly accurately predicts chronological age. We moreover describe the WID-relative epithelial age (WID-REA) which specifically captures ageing of epithelial cells, which line our organs. The WID-REA may be informative to monitor individual breast cancer risk.

Featured publication

Breast cancer prevention with antiprogestins and the WID-Breast29

Bartlett et al., 2022, Genome Medicine

We describe the potential for individualised breast cancer prevention and risk monitoring using antiprogestins and a novel type of epigenetic test, the WID-Breast29, Our findings may be particularly valuable for individuals at the highest risk, for instance BRCA mutation carriers.

Featured publications

Association between the cervicovaginal microbiome and risk of ovarian cancer

We found that ovarian cancer and its underlying risk factors (such as BRCA1 mutations) are significantly associated with alterations in the cervicovaginal microbiome. Nene et al., 2019, The Lancet Oncology

We then went on to assess whether the DNA methylation status of the cervix could predict the cervicovaginal microbiome and our findings strongly support the view that the epithelial epigenome plays an essential role in hosting specific microbial communities.  Nene et al., 2020, Clinical Epigenetics


Schreiberhuber L, Barrett JE, Wang J, Redl E, Herzog C, Vavourakis CD, Sundström K, Dillner J, Widschwendter M. Cervical cancer screening using DNA methylation triage in a real-world population. Nat Med. 2024 Jun 4. doi: 10.1038/s41591-024-03014-6. Epub ahead of print. PMID: 38834848.

Illah O, Scott M, Redl E, et al. High performance of the DNA methylation-based WID-qEC test for detecting uterine cancers independent of sampling modalities. Int J Cancer. 2024 May 13. doi: 10.1002/ijc.35000. PMID: 38739012. Online ahead of print.

Newton C, Graham R, Liberale V, et al. Outcomes of minimal access retroperitoneal para-aortic lymphadenectomy in patients with locally advanced cervical cancer. J Obstet Gynaecol. 2024 Dec;44(1):2344529. doi: 10.1080/01443615.2024.2344529. PMID: 38708782. Online ahead of print.

Falgenhauer M, Lauschensky A, Kreiner K, et al. Towards an Electronic Health Prevention Record Based on HL7 FHIR and the OMOP Common Data Model. Stud Health Technol Inform. 2024 Apr 26;313:107-112. doi: 10.3233/SHTI240020. PMID: 38682513.

Haran S, Chindera K, Sabry M, et al. Natural Killer Cell Dysfunction in Premenopausal BRCA1 Mutation Carriers: A Potential Mechanism for Ovarian Carcinogenesis. Cancers (Basel). 2024 Mar 18;16(6):1186. doi: 10.3390/cancers16061186. PMID: 38539519.

Herzog C, Jones A, Evans I, et al. Cigarette smoking and e-cigarette use induce shared DNA methylation changes linked to carcinogenesis. Cancer Res. 2024 Mar; doi: 10.1158/0008-5472.CAN-23-2957. PMID: 38503267. Online ahead of print.

Herzog C, Jones A, Evans I, et al. Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial. Int J Cancer. 2024 Feb;154(4):679-691. doi: 10.1002/ijc.34757. PMID: 37861205.

Moqri M, Herzog C, Poganik JR, et al. Validation of biomarkers of aging. Nat Med. 2024 Feb;30(2):360-372. doi: 10.1038/s41591-023-02784-9. PMID: 38355974.

Evans I, Reisel D, Jones A, et al. Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK. Lancet Oncol. 2023 Dec;24(12):1375-1386. doi: 10.1016/S1470-2045(23)00466-7. PMID: 37944542.

Herzog C, Jones A, Evans I, et al. DNA methylation at quantitative trait loci (mQTLs) varies with cell type and nonheritable factors and may improve breast cancer risk assessment. NPJ Precis Oncol. 2023 Sep;7(1):99. doi: 10.1038/s41698-023-00452-2. PMID: 37758816.

Moqri M, Herzog C, Poganik JR; Biomarkers of Aging Consortium; et al. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 2023 Aug;186(18):3758-3775. doi: 10.1016/j.cell.2023.08.003. PMID: 37657418.

Herzog C, Vavourakis CD, Barrett JE, et al. HPV-induced host epigenetic reprogramming is lost upon progression to high-grade cervical intraepithelial neoplasia. Int J Cancer. 2023 Jun;152(11):2321-2330. doi: 10.1002/ijc.34477. PMID: 36810770.

Barrett JE, Jones A, Evans I, et al. The WID-EC test for the detection and risk prediction of endometrial cancer. Int J Cancer. 2023 May;152(9):1977-1988. doi: 10.1002/ijc.34406. PMID: 36533702.

Herzog C, Sundström K, Jones A, et al. DNA methylation-based detection and prediction of cervical intraepithelial neoplasia grade 3 and invasive cervical cancer with the WID™-qCIN test. Clin Epigenetics. 2022 Nov;14(1):150. doi: 10.1186/s13148-022-01353-0. PMID: 36414968.

Barrett JE, Sundström K, Jones A, et al. The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer. Genome Med. 2023 Mar;152(6):1060-1068. doi: 10.1002/ijc.34286. PMID: 36093582.

Lehtinen M, Pimenoff V, Nedjai B, et al. Assessing the risk of cervical neoplasia in the post-HPV vaccination era. International Journal of Cancer. (2022 Sep 12). doi: 10.1002/ijc.34286. Online ahead of print. PMID: 36093582.

Schreiberhuber L, Herzog C, Vavourakis C, et al. The WIDTM-qEC test – performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers. International Journal of Cancer. 2023 Mar;152(6):1269-1274. doi: 10.1002/ijc.34275. PMID: 36056582.

Herzog C, Marín F, Jones A, et al. A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets. J Clin Oncol. 2022 Nov;40(33):3828-3838. doi: 10.1200/JCO.22.00266. PMID: 36001862.

Bartlett TE, Evans I, Jones A, et al. Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women. Genome Med. 2022 Jun;14(1):64. doi: 10.1186/s13073-022-01063-5. PMID: 35701800.

Barrett JE, Herzog C, Kim Y-N, et al. Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock. Genome Biol. 2022 Feb;23(1):52. doi: 10.1186/s13059-022-02603-3. PMID: 35189945.

Barrett JE, Herzog C, Jones A, et al. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nat Commun. 2022 Feb;13(1):449. doi: 10.1038/s41467-021-27918-w. PMID: 35105882.

Barrett JE, Jones A, Evans I, et al. The DNA methylome of cervical cells can predict the presence of ovarian cancer. Nature Commun. 2022 Feb;13(1):448. doi: 10.1038/s41467-021-26615-y. PMID: 35105887.

Martinez RM, Müller H, Negru S, et al. Human exposome assessment platform. Environ Epidemiol. 2021 Dec;5(6):e182. doi: 10.1097/EE9.0000000000000182. eCollection 2021 Dec. PMID: 34909561.

Mühlberger N, Sroczynski G, Gogollari A, et al. Cost Effectiveness of Breast Cancer Screening and Prevention – A Systematic Review with a Focus on Risk-Adapted Strategies. Eur J Health Econ. 2021 Nov;22(8):1311-1344. doi: 10.1007/s10198-021-01338-5. PMID: 34342797.

Kalsi JK, Ryan A, Gentry-Maharaj A, et al. Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplar. Trials. 2021 Jan;22(1):88. doi: 10.1186/s13063-020-04968-x. PMID: 33494753.

Kim  O, Young Park E, Young Kwon S, et al. Targeting progesterone signaling prevents metastatic ovarian cancer. PNAS. 2020 Dec;117(50):31993-32004. doi: 10.1073/pnas.2013595117. PMID: 33262282.

Nené NR, Barrett J, Jones A, et al. DNA methylation signatures to predict the cervicovaginal microbiome status. Clin Epigenetics. 2020 Nov;12(1):180. doi: 10.1186/s13148-020-00966-7. PMID: 33228781.

Bolt I, Bunnik EM, Tromp K, Pashayan N,  Widschwendter M, de Beaufort I. Prevention in the age of personal responsibility: epigenetic risk-predictive screening for female cancers as a case study. J Med Ethics. 2020 Nov;0:1–6. doi:10.1136/medethics-2020-106146. PMID: 33208479.

Sroczynski G, Gogollari A, Conrads-Frank A, Hallsson LR, Pashayan N, Widschwendter M, Siebert U. Cost-Effectiveness of Early Detection and Prevention Strategies for Endometrial Cancer-A Systematic Review. Cancers (Basel). 2020 Jul;12(7):E1874. doi: 10.3390/cancers12071874. PMID: 32664613.

Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, Sroczynski G, Hall P, Cuzick J, Evans DG, Simard J, Garcia-Closas M, Schmutzler R, Wegwarth O, Pharoah P, Moorthie S, De Montgolfier S, Baron C, Herceg Z, Turnbull C, Balleyguier C, Rossi PG, Wesseling J, Ritchie D, Tischkowitz M, Broeders M, Reisel D, Metspalu A, Callender T, de Koning H, Devilee P, Delaloge S, Schmidt MK, Widschwendter M. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat Rev Clin Oncol. 2020 Nov;17(11):687-705. doi: 10.1038/s41571-020-0388-9. Epub 2020 Jun 18. Erratum in: Nat Rev Clin Oncol. 2020 Jun 29;: PMID: 32555420.

Dilley J, Burnell M, Gentry-Maharaj A, et al. Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the ‘no screen’ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecol Oncol. 2020 Aug;158(2):316-322. doi: 10.1016/j.ygyno.2020.05.002. PMID: 32561125.

Widschwendter M and Dubeau L. Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control. Cancers. 2020 Feb;12(3). pii: E547. doi: 10.3390/cancers12030547. PMID: 32120796.

Sroczynski G, Gogollari1 A, Kuehne F, Hallsson LR, Widschwendter M, Pashayan N, Siebert U. A Systematic Review on Cost-Effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies. Cancer Prevention Research (Phila.). 2020 May;13(5):429-442. doi: 10.1158/1940-6207. PMID: 32071120.

Nene NR, Reisel D, Leimbach A et al. Association Between the Cervicovaginal Microbiome, BRCA1 Mutation Status, and Risk of Ovarian Cancer: A Case-Control Study. The Lancet Oncology. 2019 Aug;20(8):1171-1182. doi: 10.1016/S1470-2045(19)30340-7. PMID: 31300207.

Rebitschek FG, Pashayan N, Widschwendter M, Wegwarth O. Do cancer risk and benefit-harm ratios influence women's consideration of risk-reducing mastectomy? A scenario-based experiment in five European countries. PLoS One. 2019 Jun;14(6):e0218188. doi: 10.1371/journal.pone.0218188. PMID: 31188874.

Wegwarth O, Pashayan N, Widschwendter M, Rebitschek FG. Women's perception, attitudes, and intended behavior towards predictive epigenetic risk testing for female cancers in 5 European countries: a cross-sectional online survey. BMC Public Health. (2019 May 30); 19(1):667. doi: 10.1186/s12889-019-6994-8. PMID: 31146730.

Wegwarth O, Widschwendter M, Cibula D, Sundström K, Portuesi R, Lein I, Rebitschek FG, on behalf of the FORECEE (4C) Consortium. What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries. BMJ Open. 2018 Dec;8(12):e023789. doi: 10.1136/bmjopen-2018-023789. PMID: 30593552. 

Lévesque E, Kirby E, Bolt I, Knoppers BM, de Beaufort I, Pashayan N, Widschwendter M. Ethical, Legal, and Regulatory Issues for the Implementation of Omics-Based Risk Prediction of Women's Cancer: Points to Consider. Public Health Genomics. 2018;21(1-2):37-44. doi: 10.1159/000492663. PMID: 30223261.

Austria T, Marion C, Yu V, Widschwendter M, Hinton DR, Dubeau L. Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways. Int J Cancer.  2018 Dec;143(11):2932-2942. doi: 10.1002/ijc.31659. PMID: 29978915.

Alblas M, Velt KB, Pashayan N, Widschwendter M, Steyerberg EW, Vergouwe Y. Prediction models for endometrial cancer for the general population or symptomatic women: A systematic review. Crit Rev Oncol Hematol. 2018 Jun;126:92-99. doi: 10.1016/j.critrevonc.2018.03.023. PMID: 29759571.

Zheng SC, Webster AP, Dong D, Feber A, Graham DG, Sullivan R, Jevons S, Lovat LB, Beck S, Widschwendter M, Teschendorff AE. A novel cell-type deconvolution algorithm reveals substantial contamination by immune cells in saliva, buccal and cervix. Epigenomics. 2018 Jul;10(7):925-940. doi: 10.2217/epi-2018-0037. PMID: 29693419.

Nunes N, Ambler G, Foo X, Widschwendter M, Jurkovic D. Prospective evaluation of IOTA logistic regression models LR1 and LR2 in comparison with subjective pattern recognition for diagnosis of ovarian cancer in an outpatient setting. Ultrasound Obstet Gynecol. 2018 Jun;51(6):829-835. doi: 10.1002/uog.18918. PMID: 28976616.

Gao Y, Widschwendter M, Teschendorff AE. DNA Methylation Patterns in Normal Tissue Correlate more Strongly with Breast Cancer Status than Copy-Number Variants. EBioMedicine. 2018 May;31:243-252. doi: 10.1016/j.ebiom.2018.04.025. PMID: 29735413.

Widschwendter M, Jones A, Evans I, Reisel D, Dillner J, Sundström K, Steyerberg EW, Vergouwe Y, Wegwarth O, Rebitschek FG, Siebert U, Sroczynski G, de Beaufort ID, Bolt I, Cibula D, Zikan M, Bjørge L, Colombo N, Harbeck N, Dudbridge F, Tasse AM, Knoppers BM, Joly Y, Teschendorff AE, Pashayan N; FORECEE (4C) Consortium. Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nat Rev Clin Oncol. 2018 May;15(5):292-309. doi: 10.1038/nrclinonc.2018.30. Review. PMID: 29485132.

Lawn RB, Anderson EL, Suderman M, Simpkin AJ, Gaunt TR, Teschendorff AE, Widschwendter M, Hardy R, Kuh D, Relton CL, Howe LD. Psychosocial adversity and socioeconomic position during childhood and epigenetic age: analysis of two prospective cohort studies. Hum Mol Genet. 2018 Apr;27(7):1301-1308. doi: 10.1093/hmg/ddy036. PMID: 29365106.

Widschwendter M, Evans I, Jones A, Ghazali S, Reisel D, Ryan A, Gentry-Maharaj A, Zikan M, Cibula D,  Eichner J, Alunni-Fabbroni M, Koch J, Janni WJ, Paprotka T, Wittenberger T, Menon U, Wahl B, Rack B, Lempiäinen H. Methylation patterns in serum DNA for early identification of disseminated breast cancer. Genome Med. 2017 Dec;9(1):115. doi: 10.1186/s13073-017-0499-9. PMID: 29268762.

Widschwendter M, Zikan Z, Wahl B, Lempiäinen H, Paprotka T, Evans I, Jones A, Ghazali S, Reisel D, Eichner J, Rujan T, Yang Z, Teschendorff AE, Ryan A, Cibula D, Menon U, Wittenberger T. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Med. 2017 Dec;9(1):116. doi: 10.1186/s13073-017-0500-7. PMID: 29268796.

Chen Y, Widschwendter M, Teschendorff AE. Systems-epigenomics inference of transcription factor activity implicates arylhydrocarbon-receptor inactivation as a key event in lung cancer development. Genome Biol. 2017 Dec;18(1):236 DOI 10.1186/s13059-017-1366-0. PMID: 29262847.

Ong JS, Hwang LD, Cuellar-Partida G, et al. Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2018 Apr;47(2):450-459. doi: 10.1093/ije/dyx236. PMID: 29186515.

Simpkin AJ, Cooper R, Howe LD, Relton CL, Davey Smith G, Teschendorff AE, Widschwendter M, Wong A, Kuh D, Hardy R. Are objective measures of physical capability related to accelerated epigenetic age? Findings from a British birth cohort. BMJ Open. 2017 Nov;7(10):e016708. doi: 10.1136/bmjopen-2017-016708. PMID: 29092899.

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, et al. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol. 2017 Dec;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290. PMID: 29049607.

Wang Y, Teschendorff AE, Widschwendter M, Wang S. Accounting for differential variability in detecting differentially methylated regions. Brief Bioinform. 2019 Jan 18;20(1):47-57. doi: 10.1093/bib/bbx097. PMID: 29912290.

Tomar T, Alkema NG, Schreuder L, Meersma GJ, de Meyer T, van Criekinge W, Klip HG, Fiegl H, van Nieuwenhuysen E, Vergote I, Widschwendter M, Schuuring E, van der Zee AGJ, de Jong S, Wisman GBA. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. BMC Med. 2017 Jun;15(1):116. doi: 10.1186/s12916-017-0870-0. PMID: 28641578.

Nunes N, Ambler G, Foo X, Naftalin J, Derdelis G, Widschwendter M, Jurkovic D. Comparison of two protocols for the management of asymptomatic postmenopausal women with adnexal tumours - a randomised controlled trial of RMI/RCOG vs Simple Rules. Br J Cancer. 2017 Feb;116(5):584-591. doi: 10.1038/bjc.2017.17. Epub 2017 Feb 2. PMID: 28152542.

Wong M, Crnobrnja B, Liberale V, Dharmarajah K, Widschwendter M, Jurkovic D. The natural history of endometrial polyps. Hum. Reprod. 2017 Feb;32(2):340-345. doi: 10.1093/humrep/dew307. PMID: 27994000.

Kazarian A, Blyuss O, Metodieva G, Gentry-Maharaj A, Ryan A, Kiseleva EM, Prytomanova OM, Jacobs IJ, Widschwendter M, Menon U, Timms JF. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. Br J Cancer. 2017 Feb;116(4):501-508. doi: 10.1038/bjc.2016.433. PMID: 28081538.

Milani A, Kristeleit R, McCormack M, Raja F, Luvero D, Widschwendter M, MacDonald N, Mould T, Olatain A, Hackshaw A, Ledermann JA. Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy. ESMO Open. 2017 Jan;1(6):e000117. doi: 10.1136/esmoopen-2016-000117. eCollection 2016. PMID:28848659.

Marchetti C, Kristeleit R, McCormack M, Mould T, Olaitan A, Widschwendter M, MacDonald N, Ledermann JA. Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review. Gynecol Oncol. 2017 Jan;144(1):57-60. doi: 10.1016/j.ygyno.2016.11.001.PMID: 27825669.

Kiechl S, Schramek D, Widschwendter M, Fourkala EO, Zaikin A, Jones A, Jaeger B, Rack B, Janni W, Scholz C, Willeit J, Weger S, Mayr A, Teschendorff A, Rosenthal A, Fraser L, Philpott S, Dubeau L, Keshtgar M, Roylance R, Jacobs IJ, Menon U, Schett G, Penninger JM. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. Oncotarget. 2017 Jan;8(3):3811-3825. doi: 10.18632/oncotarget.14013.PMID: 28002811.

Yang Z, Wong A, Kuh D, Paul D, Rakyan VK, Leslie RD, Zheng SC, Widschwendter M, Beck S, Teschendorff AE. Correlation of an epigenetic mitotic clock with cancer risk. Genome Biol. 2016 Oct;17(1):205. PMID: 27716309.

Kalwa M, Haenzelmann S, Otto S, Kuo C-C, Franzen J, Joussen S, Fernandez Rebollo E, Rath B, Koch C, Hofmann A, Lee S-H, Teschendorff A, Denecke B, Lin Q, Widschwendter M, Weinhold E, Costa I, Wagner W. The lncRNA HOTAIR Impacts on Mesenchymal Stem Cells via Triple Helix Formation. Nucl Acid Res. 2016 Sep;44(22):10631-10643. PMID: 27634931.

Teschendorff AE, Zheng SC, Feber A, Yang Z, Beck S, Widschwendter M. The multi-omic landscape of transcription factor inactivation in cancer. Genome Med. 2016 Aug;8(1):89. doi: 10.1186/s13073-016-0342-8. PMID: 27562343.

Levine ME, Lu AT, Chen BH, Hernandez DG, Singleton AB, Ferrucci L, Bandinelli S, Salfati E, Manson JE, Quach A, Kusters CDJ, Kuh D, Wong A, Teschendorff AE, Widschwendter M, Ritz BR, Absher D, Assimes T, Horvath S. Menopause Accelerates Biological Aging. Proc Natl Acad Sci USA. 2016 Aug;113(33):9327-32. doi: 10.1073/pnas.1604558113. PMID: 27457926.

Lemech CR, Ensell L, Paterson JC, Eminowicz G, Lowe H, Arora R, Arkenau HT, Widschwendter M, MacDonald N, Olaitan A, Mould T, Meyer T, Hartley J, Mitra A, Ledermann JA, McCormack M, Kristeleit RS. Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer. Oncology. 2016;91(1):48-54. doi: 10.1159/000445999. PMID: 27256106.

Doufekas K, Zheng SC, Ghazali S, Wong M, Mohamed Y, Jones A, Reisel D, Mould T, Olaitan A, Macdonald N, Teschendorff A, Widschwendter M. DNA methylation signatures in vaginal fluid samples for detection of cervical and endometrial cancer. Int J Gynecol Cancer. 2016 Jun. doi: 10.1097/IGC.0000000000000739. PMID: 27258725. Online ahead of print.

Gao Y, Jones A, Fasching P, Ruebner M, Beckmann MW, Widschwendter M and Teschendorff A. The integrative epigenomic-transcriptomic landscape of ER positive breast cancer. Clin Epigenetics. 2016 Jun;8:63. doi: 10.1186/s13148-016-0231-4. Erratum for: Clin Epigenetics. 2015;7:126. PMID: 27257442; PMCID: PMC4890493.

Bartlett TE, Chindera K, McDermott J, Breeze C, Cooke WR, Jones A, Reisel D, Karegodar ST, Arora R, Beck S, Menon U, Dubeau L, Widschwendter M. Epigenetic reprogramming of Fallopian tube fimbriae in BRCA mutation carriers defines ovarian cancer evolution. Nature Communications. 2016 May;7:11620. doi: 10.1038/ncomms11620. PMID: 27216078.

Lim A, Mesher D, Gentry-Maharaj A, Balogun N, Widschwendter M, Jacobs I, Sasieni P, Menon U. Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records. BJOG. 2016 May;123(6):1012-20. doi: 10.1111/1471-0528.13447. Epub 2015 May 29. PMID: 26032603.

Zheng SC, Widschwendter M, Teschendorff AE. Epigenetic drift, epigenetic clocks and cancer risk. Epigenomics. 2016 May;8(5):705-19. doi: 10.2217/epi-2015-0017. PMID: 27104983.

Teschendorff AE, Jones A, Widschwendter M. Stochastic epigenetic outliers can define field defects in cancer. BMC Bioinformatics. 2016 Apr;17:178. doi: 10.1186/s12859-016-1056-z. PMID: 27103033.

Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. The Lancet. 2016 Mar;387(10022):945-56. doi: 10.1016/S0140-6736(15)01224-6. PMID: 26707054. 

Pashayan N, Reisel D, Widschwendter M. Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges. Pers Med. 2016 Mar; 13(2):93-95. doi: 10.2217/pme.15.53. PMID: 27053939.

Teschendorff AE Gao Y, Jones A, Ruebner M, Beckmann MW, Wachter DL, Fasching PA, Widschwendter M.DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. Nature Communications. 2016 Jan;7:10478. doi: 10.1038/ncomms10478. PMID: 26823093.

Pharoah PDP, Song H, Dicks E, Intermaggio MP, Harrington P, Baynes C, Alsop K, AOCS Study Group Bogdanova N, Cicek MS, Cunningham JM, Fridley BL, Gentry-Maharaj A, Hillemanns P, Lele S, Lester J, McGuire V, Moysich KB, Poblete S, Sieh W, Sucheston-Campbell L, Widschwendter M, Ovarian Cancer Association Consortium, Whittemore AS, Dörk T, Menon U, Odunsi K, Goode EL, Karlan BY, Bowtell DD,Gayther SA, Ramus SJ. PPM1D mosaic truncating variants in ovarian cancer cases may be treatment related somatic mutations. Journal of the National Cancer Institute. 2016 Jan;108(3):djv347. doi: 10.1093/jnci/djv347. PMID: 26823519.

Paul DS, Jones A, Sellar RS, Mayor NP, Feber A, Webster AP, Afonso N, Sergeant R, Szydlo RM, Apperley JF, Widschwendter M, Mackinnon S, Marsh SGE, Madrigal JA, Rakyan VK, Peggs KS, Beck S. A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation. Genome Med. 2015 Dec;7:128. doi: 10.1186/s13073-015-0246-z. PMID: 26669438.

Bartlett TE, Jones A, Goode EL, Fridley BL, Cunningham JM, Berns EMJJ, Wik E, Salvesen HB, Davidson B, Trope CG, Lambrechts S, Vergote I, Widschwendter M. Intra-Gene DNA Methylation Variability is a Clinically Independent Prognostic Marker in Women's Cancers. PLoS One. 2015 Dec;10(12):e0143178. doi: 10.1371/journal.pone.0143178. PMID: 26629914.

Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S, Vergote I, Calvert H, Jacobs IJ, Widschwendter M. HOTAIR And Its Surrogate DNA Methylation Signature Indicate Carboplatin Resistance In Ovarian Cancer. Genome Med. 2015 Oct;7(1):108. doi: 10.1186/s13073-015-0233-4. PMID: 26497652.

Liu Y, Pike MC, Wu N, Lin YG, Mucowski S, Punj V, Tang Y, Yen HY, Stanczyk FZ, Enbom E, Austria T, Widschwendter M, Maxson R, Dubeau L. Brca1 Mutations Enhance Mouse Reproductive Functions by Increasing Responsiveness to Male-Derived Scent. PLoS One. 2015 Oct;10(10):e0139013. doi: 10.1371/journal.pone.0139013. PMID: 26488398.

Liu Y, Yen HY, Austria T, Pettersson J, Peti-Peterdi J, Maxson R, Widschwendter M, Dubeau L. A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State.mutation carrier state. EBioMedicine. (2015 Sep 09); 2(10): 1318–1330. doi.org/10.1016/j.ebiom.2015.08.034. PMID: 26629527.

Widschwendter M, Burnell M, Fraser S, Rosenthal AN, Philpott S, Reisel D, Dubeau L, Cline M, Pan Y, Ping-Cheng Y, Evans DG, Jacobs IJ, Menon U, Wood CE, Dougall WC. Osteoprotegerin (OPG), the Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine. 2015 Sep;2(10): 1331–1339. doi.org/10.1016/j.ebiom.2015.08.037. PMID: 26629528.

Yang Z, Jones A, Widschwendter M, Teschendorff AE. An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer. Genome Biol. 2015 Jul;16(1):140. doi: 10.1186/s13059-015-0699-9. PMID: 26169266.

Teschendorff AE, Yang Z, Wong A, Pipinikas CP, Jiao Y, Jones A, Anjum S, Hardy R, Salvesen HB, Thirlwell C, Janes SM, Kuh D, Widschwendter M. Correlation of Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer. JAMA Oncol. 2015 Jul;1(4):476-85. doi: 10.1001/jamaoncol.2015.1053. PMID: 26181258.

Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol. 2015 Jun;33(18):2062-71. doi: 10.1200/JCO.2014.59.4945. PMID: 25964255.

Del Rincón SV, Widschwendter M, Sun D, Ekholm-Reed S, Tat J, Teixeira LK, Ellederova Z, Grolieres E, Reed SI, Spruck C. Cks Overexpression Enhances Chemotherapeutic Efficacy by Overriding DNA Damage Checkpoints. Oncogene. 2015 Apr;34(15):1961-7. doi: 10.1038/onc.2014.137. PMID: 24858038.

Köbel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, Odunsi K, Menon U, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A, Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Høgdall E, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H, Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE, George J, Galletta L; AOCS Study Group, Goode EL, Kjær SK, Huntsman DG, Fasching PA, Moysich KB, Brenton JD, Kelemen LE. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer. 2014 Dec;111(12):2297-2307. doi: 10.1038/bjc.2014.567. PMID: 25349970.

Nunes N, Ambler G, Foo X, Naftalin J, Widschwendter M, Jurkovic D. Use of IOTA Simple Rules for the diagnosis of ovarian cancer: a Meta-Analysis. Ultrasound Obstet Gynecol. 2014 Nov;44(5):503-14. doi: 10.1002/uog.13437. PMID: 24920435.

Asghar US, Imseeh G, Kirkwood AA, Widschwendter M, Olaitan A, Macdonald N, Mould T, McCormack M, Mitra A, Ledermann JA, Arora R, Kristeleit R. 930PA Retrospective Single Institution Study Evaluating Clinical Outcome and Prognostic Markers for Endometrial and Ovarian Carcinosarcomas (CS). Ann Oncol. 2014 Sep;25(suppl_4):iv322. doi: 10.1093/annonc/mdu338.54.

Loddo M, Andryszkiewicz J, Rodriguez-Acebes S, Stoeber K, Jones A, Dafou D, Apostolidou S, Wollenschlaeger A, Widschwendter M, Sainsbury R, Tudzarova S, Williams GH. Pregnancy-associated plasma protein A regulates mitosis and is epigenetically silenced in breast cancer. J Pathol. 2014 Aug;233(4):344-56. doi: 10.1002/path.4393. PMID: 24931331.

Jiao Y, Widschwendter M, Teschendorff AE. A systems-level integrative framework for genome-wide DNA methylation and gene expression data identifies functional gene modules under epigenetic control. Bioinformatics 2014 Aug;30(16):2360-6. doi: 10.1093/bioinformatics/btu316. PMID: 24794928.

Teschendorff AE, Liu X, Caren H, Pollard SM, Beck S, Widschwendter M, Chen L. The Dynamics of DNA Methylation Covariation Patterns in Carcinogenesis. PLoS Comput Biol. 2014 Jul;10(7): e1003709. doi: 10.1371/journal.pcbi.1003709. PMID: 25010556.

Anjum S, Fourkala E-O, Zikan M, Wong A, Gentry-Maharaj A, Jones A, Hardy R, Cibula D, Kuh D,  Jacobs IJ, Teschendorff AE, Menon U,  Widschwendter M. A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome Med. 2014 Jun;6(6):47. doi: 10.1186/gm567. PMID: 25067956.

Almouzni G, Altucci L, Amati B, Ashley N, Baulcombe D, Beaujean N, Bock C, Bongcam-Rudloff E, Bousquet J, Braun S, Paillerets BB, Bussemakers M, Clarke L, Conesa A, Estivill X, Fazeli A, Grgurević N, Gut I, Heijmans BT, Hermouet S, Houwing-Duistermaat J, Iacobucci I, Ilaš J, Kandimalla R, Krauss-Etschmann S, Lasko P, Lehmann S, Lindroth A, Majdič G, Marcotte E, Martinelli G, Martinet N, Meyer E, Miceli C, Mills K, Moreno-Villanueva M, Morvan G, Nickel D, Niesler B, Nowacki M, Nowak J, Ossowski S, Pelizzola M, Pochet R, Potočnik U, Radwanska M, Raes J, Rattray M, Robinson MD, Roelen B, Sauer S, Schinzer D, Slagboom E, Spector T, Stunnenberg HG, Tiligada E, Torres-Padilla ME, Tsonaka R, Soom AV, Vidaković M, Widschwendter M. Relationship between genome and epigenome - challenges and requirements for future research. BMC Genomics. 2014 Jun;15:487.  doi:10.1186/1471-2164-15-487. PMID: 24942464.

Wittenberger T, Sleigh S, Reisel D, Zikan M, Wahl B, Alunni-Fabbroni M, Jones A, Evans I, Koch J, Paprotka T, Lempiäinen H, Rujan T, Rack B, Cibula D, Widschwendter M. DNA methylation markers for early detection of women’s cancer: promise and challenges. Epigenomics. 2014 Jun;6(3):311-27. doi: 10.2217/epi.14.20. PMID: 25111485.

Tan Y, Sun D, Jiang W, Klotz-Noack K, Vashisht AV, Wohlschlegel J, Widschwendter M, Spruck C. PP2A-B55β Antagonizes Cyclin E1 Proteolysis and Promotes its Dysregulation in Cancer. Cancer Res. 2014 Apr;74(7):2006-14. doi: 10.1158/0008-5472.CAN-13-1263. PMID: 24509904. 

Hoivik EA, Kusonmano K, Halle MK, Berg A, Wik E, Werner HM, Petersen K, Oyan AM, Kalland KH, Krakstad C, Trovik J, Widschwendter M, Salvesen HB. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. Oncotarget. 2014 Feb;5(4):1052-61. doi: 10.18632/oncotarget.1697. PMID: 24658009.

Jones A, Teschendorff AE, Li Q, Hayward JD, Kannan A, Mould T, West J, Zikan M, Cibula D, Fiegl H, Lee S-H, Wik E, Hadwin R, Arora R, Lemech C, Turunen H, Pakarinen P, Jacobs IJ, Salvesen HB, Bagchi MK, Bagchi IC, Widschwendter M. Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development. PLoS MED. 2013 Nov;10(11):e1001551. doi: 10.1371/journal.pmed.1001551. PMID: 24265601.

Banerji CR, Miranda-Saavedra D, Severini S, Widschwendter M, Enver T, Zhou JX, Teschendorff AE. Cellular network entropy as the energy potential in Waddington’s differentiation landscape. Scientific Reports. 2013 Oct;3:3039. doi: 10.1038/srep03039. PMID: 24154593.

Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, Intermaggio MP, Edlund CK, Ramus SJ, Gayther SA, Dubeau L, Fourkala EO, Zaikin A, Menon U, and Jacobs IJ. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. The Lancet Oncology. 2013 Nov;14(12):1226-32. doi: 10.1016/S1470-2045(13)70448-0. PMID: 24140203.

Nunes N, Ambler G, Hoo WL, Naftalin J, Foo X, Widschwendter M, Jurkovic D. A Prospective Validation of the IOTA Logistic Regression Models (LR1 and LR2) in Comparison to Subjective Pattern Recognition for the Diagnosis of Ovarian Cancer. Int J Gynecol Cancer. 2013 Nov;23(9):1583-9. doi: 10.1097/IGC.0b013e3182a6171a. PMID: 24088790.

West J, Widschwendter M, Teschendorff AE. Distinctive topology of age-associated epigenetic drift in the human interactome. Proc Natl Acad Sci USA 2013 Aug;110(35):14138-43. doi: 10.1073/pnas.1307242110. PMID: 23940324.

Bartlett TE, Zaikin A, Olhede SC, West J, Teschendorff AE, Widschwendter M. Corruption of the intra-gene DNA methylation architecture is a hallmark of cancer. PLoS One. 2013 Jul;8(7):e68285. doi: 10.1371/journal.pone.0068285. PMID: 23874574.

Cepeda D, Ng HF, Sharifi HR, Mahmoudi S, Cerrato VS, Fredlund E, Magnusson K, Nilsson H, Malyukova A, Rantala J, Klevebring D, Viñals F, Bhaskaran N, Zakaria SM, Rahmanto AS, Grotegut S, Nielsen ML, Szigyarto CA, Sun D, Lerner M, Navani S, Widschwendter M, Uhlén M, Jirström K, Pontén F, Wohlschlegel J, Grandér D, Spruck C, Larsson LG, Sangfelt O. CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med. 2013 Jul;5(7):999-1018. doi: 10.1002/emmm.201202341. PMID: 23776131.

Doufekas K, Hadwin R, Kandimalla R, Jones A, Mould T, Crowe S, Olaitan A, Macdonald N, Fiegl H, Wik E, Salvesen HB, Widschwendter M. GALR1 Methylation in Vaginal Swabs Is Highly Accurate in Identifying Women With Endometrial Cancer. Int J Gynecol Cancer. 2013 Jul;23(6): 1050-5. doi: 10.1097/IGC.0b013e3182959103. PMID: 23727823

Widschwendter M, Jones A, Teschendorff AE. Epigenetics makes its mark on women-specific cancers--an opportunity to redefine oncological approaches? Gynecol Oncol. 2013 Jan;128(1):134-43. doi: 10.1016/j.ygyno.2012.09.027. PMID: 23036354..

Nunes N, Foo X, Widschwendter M, Jurkovic D. A randomised controlled trial comparing surgical intervention rates between two protocols for the management of asymptomatic adnexal tumours in postmenopausal women. BMJ Open. 2012 Dec;2(6). doi:pii: e002248. 10.1136/bmjopen-2012-002248. Print 2012. PMID: 23233701.

Balogun N, Forbes A, Widschwendter M, Lanceley A. Noninvasive nutritional management of ovarian cancer patients: beyond intestinal obstruction. Int J Gynecol Cancer. 2012 Jul;22(6):1089-95. doi: 10.1097/IGC.0b013e318256e4d3. PMID: 22688964.

Teschendorff AE and Widschwendter M. Differential variability improves the identification of cancer risk markers in DNA methylation studies profiling precursor cancer lesions. Bioinformatics. 2012 Jun;28(11):1487-94. doi: 10.1093/bioinformatics/bts170. PMID: 22492641.

Fourkala EO, Gentry-Maharaj A, Burnell M, Ryan, A, Manchanda R, Dawnay A, Jacobs I, Widschwendter M, Menon U. Histological confirmation of breast cancer registration and self-reporting in England and Wales: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. British Journal of Cancer. 2012 Jun;106(12):1910-6. doi: 10.1038/bjc.2012.155. PMID: 22596242.

Zhuang J, Widschwendter M, Teschendorff AE. A comparison of feature selection and classification methods in DNA methylation studies using the Illumina Infinium platform. BMC Bioinformatics. 2012 Apr;13:59. doi: 10.1186/1471-2105-13-59. PMID: 22524302.

Fourkala EO, Zaikin A, Burnell M, Gentry-Maharaj A, Ford J, Gunu R, Soromani C, Hasenbrink G, Jacobs I, Dawnay A, Widschwendter M, Lichtenberg-Fraté H, Menon U. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. Endocr Relat Cancer. 2012 Apr;19(2):137-47. doi: 10.1530/ERC-11-0310. Print 2012 Apr. PMID: 22199143.

Teschendorff AE, Jones A, Fiegl H, Sargent A, Zhuang J, Kitchener H & Widschwendter M. Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Medicine. 2012 Mar;4(3):24. doi: 10.1186/gm323. PMID: 22453031.

Zhuang J, Jones A, Lee SH, Ng E, Fiegl H, Zikan M, Cibula D, Sargent A, Salvesen HB, Jacobs IJ, Kitchener HC, Teschendorff AE, Widschwendter M. The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women’s Cancer. PLoS Genet. 2012 Feb;8(2):e1002517. doi: 10.1371/journal.pgen.1002517. PMID: 22346766.

Rosenthal AN, Heron G, Widschwendter M, Read S, Brunell C, Mould TA. Fooled by the film: delayed diagnosis of incarcerated small-bowel hernia after laparoscopic surgery for endometrial cancer. Int J Gynecol Cancer. 2012 Feb;22(2):337-9. doi: 10.1097/IGC.0b013e31823c244b. PMID: 22193712.

Liberal, V., Martinsson-Ahlzén, H., Liberal, J., Spruck, C., Widschwendter, M., McGowan, C., and Reed SI. Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins. Proc Natl Acad Sci USA. 2012 Feb;109(8):2754-9. doi: 10.1073/pnas.1102434108. PMID: 21697511.

Goebel G, Berger R, Strasak M, Egle D, Mueller-Holzner E, Schmidt S, Rainer J, Presul E, Lang S, Jones A, Widschwendter M and Fiegl H. Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients. Brit J Cancer. 2012 Jan;106(1):189-98. doi: 10.1038/bjc.2011.510. PMID: 22108517.

Campan M, Moffitt M, Houshdaran S, Shen H, Widschwendter M, Daxenbichler G, Long T, Marth C, Laird-Offringa IA, Press MF, Dubeau L, Siegmund KD, Wu AH, Groshen S, Chandavarkar U, Roman LD, Berchuck A, Pearce CL, Laird PW. Genome-Scale Screen for DNA Methylation-Based Detection Markers for Ovarian Cancer. PLoS One. 2011;6(12):e28141. doi: 10.1371/journal.pone.0028141. PMID: 22163280.

Koukoura O, Sifakis S, Soufla G, Zaravinos A, Apostolidou S, Jones A, Widschwendter M, Spandidos DA. Loss of imprinting and aberrant methylation of IGF2 in placentas from pregnancies complicated with fetal growth restriction. Int J Mol Med. 2011Oct;28(4):481-7. doi: 10.3892/ijmm.2011.754. PMID: 21805044.

Teschendorff AE, Zhuang J, Widschwendter M. Independent Surrogate Variable Analysis as a tool to deconvolve confounding factors in large-scale microarray profiling studies. Bioinformatics. 2011 Jun;27(11):1496-505. doi: 10.1093/bioinformatics/btr171. PMID: 21471010.

Cibula D, Widschwendter M, Zikan M, Dusek L. Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet Gynecol Scand. 2011 Jun;90(6):559-63. doi: 10.1111/j.1600-0412.2011.01114.x. PMID: 21355863.

Cibula D, Widschwendter M, Dušek L. Tubal Ligation and the Risk of Ovarian Cancer – review and meta-analysis. Hum Reprod Update. 2011 Jan-Feb;17(1):55-67. doi: 10.1093/humupd/dmq030. PMID: 20634209.

Koukoura O, Sifakis S, Zaravinos A, Apostolidou S, Jones A, Hajiioannou J, Widschwendter M, Spandidos DA. Hypomethylation along with increased H19 expression in placentas from pregnancies complicated with fetal growth restriction. Placenta. 2011 Jan;32(1):51-7. doi: 10.1016/j.placenta.2010.10.017. PMID: 21129773.

Akhoondi S, Lindstrom L, Widschwendter M, Corcoran M, Bergh J, Spruck C, Grander D, Sangfelt O. Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res. 2010;12(6):R105. doi: 10.1186/bcr2788. PMID: 21122106.

Balogun N, Gentry-Maharaj A, Wozniak EL, Lim A, Ryan A, Ramus SJ, Ford J, Burnell M, Widschwendter M, Gessler SF, Gayther SA, Jacobs IJ, Menon U. Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. J Clin Epidemiol. 2011 May;64(5):525-30. doi: 10.1016/j.jclinepi.2010.07.008. PMID: 21074968.

Schramek D, Leibbrandt A, Sigl V, Kenner L, Hanada R, Joshi P,  Pospisilik JA, Lee H, Aliprantis A, Ormandy C, Glimcher L, Pasparakis M, Khoka R, Widschwendter M, Schett G, and Penninger JM. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010 Nov;468(7320):98-102. doi: 10.1038/nature09387. PMID: 20881962.

Goode E, Chenevix-Trench G, Song H, Ramus S , Notaridou M , Lawrenson K, Widschwendter M, et al., Ovarian Cancer Association Consortium. A Genome-Wide Association Study Identifies Susceptibility Loci for Ovarian Cancer at 2q31 and 8q24. Nat Genet. 2010 Oct;42(10):874-9. doi: 10.1038/ng.668. PMID: 20852632.

del Rincón S, Rogers J, Widschwendter M, Sun D, Sieburg HB, and Spruck C. Development and Validation of a Method for Profiling Post-Translational Modification Activities Using Protein Microarrays. PLoS One. 2010 Jun;5(6):e11332. doi: 10.1371/journal.pone.0011332. PMID: 20596523.

Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle D, Reimer D, Muller-Holzner E, Jones A & Widschwendter M. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. 2010 Apr;101(4):1059-66. doi: 10.1111/j.1349-7006.2010.01491.x. PMID: 20156214.

Thirlwell C, Eymard M, Feber A, Teschendorff  A, Pearce K, Lechner M, Widschwendter M, Beck S. Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium Human Methylation27 BeadChip. Methods. 2010 Nov;52(3):248-54. doi: 10.1016/j.ymeth.2010.04.012. PMID: 20434562.

Fourkala EO, Hauser-Kronberger C, Apostolidou S, Burnell M, Jones A, Grall J, Reitsamer R, Fiegl H, Jacobs I, Menon U & Widschwendter M. DNA methylation of polycomb group target genes in cores taken from breast cancer centre and periphery. Breast Cancer Res Treat. 2010 Apr;120(2):345-55. doi: 10.1007/s10549-009-0384-3. PMID: 19353266.

Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, Campan M, Noushmehr H, Bell CG, Maxwell AP, Savage DA, Mueller-Holzner E, Marth C, Kocjan G, Gayther SA, Jones A, Beck S, Wagner W, Laird PW, Jacobs IJ & Widschwendter M. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res. 2010 Apr;20(4):440-6. doi: 10.1101/gr.103606.109. PMID: 20219944.

Jones A, Lechner M, Fourkala EO, Kristeleit R, Widschwendter M. Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers. Epigenomics. 2010 Feb;2(1):9-38. doi: 10.2217/epi.09.47. PMID: 22122746.

Widschwendter M, Apostolidou S, Jones AA, Fourkala EO, Arora R, Pearce CL, Frasco MA, Ayhan A, Zikan M, Cibula D, Iyibozkurt CA, Yavuz E, Hauser-Kronberger C, Dubeau L, Menon U & Jacobs IJ. HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study. Int J Cancer. 2009 Nov 1;125(9):2214-8. doi: 10.1002/ijc.24599. PMID: 19621443.

Teschendorff AE. Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, Jones A, Lechner M, Beck S, Jacobs IJ & Widschwendter M. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One. 2009 Dec;4(12):e8274. doi: 10.1371/journal.pone.0008274. PMID: 20019873.

Apostolidou S, Hadwin R, Burnell M, Jones A, Baff D, Pyndiah N, Mould T, Jacobs IJ, Beddows S, Kocjan G, Widschwendter M. DNA methylation analysis in liquid-based cytology for cervical cancer screening. Int J Cancer. 2009 Dec;125(12):2995-3002. doi: 10.1002/ijc.24745. PMID: 19609949.

Widschwendter M, Lichtenberg-Frate H, Hasenbrink G, Schwarzer S, Dawnay A, Lam A, Menon U, Apostolidou S, Raum E, Stegmaier C, Jacobs IJ, Brenner H. Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study. Br J Cancer. 2009 Jul;101(1):160-5. doi: 10.1038/sj.bjc.6605106. PMID: 19491898.

Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, Stegmaier C, Jacobs IJ, Brenner H. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One. 2008 Jul;3(7):e2656. doi: 10.1371/journal.pone.0002656. PMID: 18628976.

Fiegl H, Jones A, Hauser-Kronberger C, Hutarew G, Reitsamer R, Jones RL, Dowsett M, Mueller-Holzner E, Windbichler G, Daxenbichler G, Goebel G, Ensinger C, Jacobs I, Widschwendter M. Methylated NEUROD1 promoter is a marker for chemonsensitivity in breast cancer. Clin Cancer Res. 2008 Jun;14(11):3494-502. doi: 10.1158/1078-0432.CCR-07-4557. PMID: 18519782.

Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ, Widschwendter M. HOXA11 DNA methylation – a novel prognostic biomarker in ovarian cancer. Int J Cancer. 2008 Aug;123(3):725-9. doi: 10.1002/ijc.23563. PMID: 18478570.

Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Zali MR, Hansson J, Egyhazi S, Petersson F, Sangfelt P, Nordgren H, Grander D, Reed SI, Widschwendter M, Sangfelt O, Spruck C. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. (2007 Oct 1); 67(19):9006-12. Erratum in: Cancer Res. 2007 Oct;67(19):9006-12. doi: 10.1158/0008-5472.CAN-07-1320. PMID: 17909001.

Learn more about EUTOPS


Martin Widschwendter is Professor for Cancer Prevention and Screening and the Director of the European Translational Oncology Prevention and Screening (EUTOPS) Institute.

The team

Find out who is contributing to our vision.


We strongly believe in collaborative work.


Read our scientific publications.

Open positions

We are always interested in working with talented scientists.